Meetings
- [NEW] 24 Jan 2023 (virtual, 17.00-18.30 CET) Webinar entitled “Delivery systems in antibacterial drug discovery.” Sponsored by GARDP, this webinar will survey the use of phage, DNA nanostructures, and nanocarriers for drug delivery. Go here for details.
- [NEW] 27 Jan 2023 (virtual, 10.00-14.00 ET): “The Challenges,” part 1 of a 2-part series entitled “Improving the Investigation of New Antibacterial Agents for Use in Children.” Convened by I-ACT (Institute for Advanced Clinical Trials for Children) and chaired by I-ACT’s Chief Medical Officer (Gary Noel), this webinar series features an outstanding faculty from Industry, Academia, and Regulatory (both FDA and EMA). Go here for details and to register.
- 1-2 Feb 2023 (virtual): Antimicrobial Chemotherapy Conference by GARDP and BSAC in collaboration with ReAct Africa and Africa CDC. Go here for details.
- [NEW] 2 Feb 2023 (virtual, 10.00-14.00 ET): “Addressing The Challenges,” part 2 of a 2-part series entitled “Improving the Investigation of New Antibacterial Agents for Use in Children.” Convened by I-ACT (Institute for Advanced Clinical Trials for Children) and chaired by I-ACT’s Chief Medical Officer (Gary Noel), this webinar series features an outstanding faculty from Industry, Academia, and Regulatory (both FDA and EMA). Go here for details and to register.
- 16-17 Mar 2023 (timings suggest hybrid EU-US): 7th AMR Conference, hosted by the BEAM Alliance with many co-sponsors. This has historically been a very good networking event. Go here for details.
- 14 Apr 2023 (Copenhagen, Denmark; 3-6.30p CEST): ECCMID and the Global Leaders Group on AMR will jointly sponsor a symposium entitled “Forging partnerships between science and policy in Antimicrobial Resistance (AMR).” Go here to register.
- 15-18 Apr 2023 (Copenhagen, Denmark): 33rd ECCMID. Go here for details and to register.
- 8-12 May 2023 (Lisbon, Portugal): 41st Annual Meeting of the European Society for Paediatric Infectious Diseases. Go here for details.
- [UPDATED DATES] 7-15 Oct 2023 (residential, Annecy, France): ICARe, the Interdisciplinary Course on Antibiotics and Resistance. Now in its 7th year, this course is a deep-dive into the world of antibiotic development. Intense, rigorous, and HIGHLY recommended. Seats are always limited … apply sooner rather than later! Go here for details.
- 20-23 Oct 2023 (Athens, Greece): 11th TIMM (Trends in Medical Mycology). Go here for details.
Share
JPIAMR Diagnostics Call / James Bond’s occupational exposures
Dear All, A short one today! Please peruse both the funding opportunities and upcoming meetings just below my signature. Of special note: Building on the call in the recent biodefense-focused BAA from NIAID for diagnostic applications, JPIAMR is also looking for diagnostic applications (7 Mar deadline). Very interesting 2 Mar 2023 Duke-Margolis webinar entitled “Data Capture
NIAID BAA – Biodefense focus / Fireside Chat on diagnostics and more
Dear All, We are swimming in Broad Agency Announcements aka BAAs! As a refresher, I recently shared a BAA from the CDC and one from BARDA — now we have another one from NIAID! There’s a strong biodefense angle here with lots of scope. Key details of each opportunity are as follows and I highly recommend you check
LPAD/Limited Use insights; NI margins for TB and candidiasis
Dear All, I want to call your attention to next week’s AMDAC (Antimicrobial Drugs Advisory Committee) for rezafungin. This meeting is Tue 24 Jan 2023, 9a-4.30p ET and the meeting materials are provided here. Rezafungin is an antifungal but please don’t let that dissuade you from attending: this AMDAC promises to be an important discussion
Notable webinars: Pediatric drug development; Drug delivery systems
Dear All, The high-value webinars below have just crossed my radar. First up, we have a very important 2-part webinar on pediatric antibacterial drug development entitled “Improving the Investigation of New Antibacterial Agents for Use in Children: Ensuring That Our Youngest Patients Also Benefit from Innovative Treatments of Infections Caused by Multi-Drug Resistant Bacteria.” Here are the
